Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.

Proteolysis-targeting chimeras (PROTACs), particularly those incorporating the von Hippel–Lindau (VHL) E3 ligase ligand, present significant physicochemical challenges due to their large molecular ...

Metastatic cells are characterised as being highly invasive but weakly adhesive with rounded-amoeboid like features. These cells harbour high levels of cortical Myosin II activity and exert low ...

From ground-breaking clinical trials to innovative discoveries, The Institute of Cancer Research, London, has been pioneering new screening tools and treatments for prostate cancer for decades. One of ...

In a major step forward for cancer drug discovery, researchers have demonstrated how computational simulations can unravel the complex role of water molecules in drug ...

Our clinical PhD fellowships are provided to develop and support future leaders in clinical cancer research. The Clinical Academic Training Programme, ICR-Imperial is a programme which will provide ...

We have an outstanding record of scientific achievement dating back more than 100 years. Here are some of our most influential discoveries, all of which have played an important role in shaping our ...

Through studies that were amongst the largest of their kind, we identified several genes involved in breast and/or ovarian cancer predisposition such as CHEK2, BRIP1, ATM, PALB2, RAD51C and RAD51D.

We provided the first conclusive evidence that the basic cause of cancer is damage to DNA. The discovery changed scientific opinion dramatically and marked a turning point for cancer research.

We pioneered the application of evolutionary biology to cancer and established cancer stem cells as the units of natural selection.

We transformed care for advanced prostate cancer, by validating inhibitors of androgen production as an effective cancer treatment, and discovering and developing abiraterone, a life-extending ...

We applied the principle of synthetic lethality to discover a novel strategy for cancer treatment for patients with BRCA1 or BRCA2 gene mutations.